Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results

Conclusions
Vedolizumab did not alter the response to parenterally administered antigens but reduced the response to oral antigens, demonstrating its gut-selective mechanism of action.

Trial registration number
NCT Number: 01981616; EudraCT Number: 2011-001874-24.

Source: Gut - December 8, 2014 Category: Gastroenterology Authors: Wyant, T., Leach, T., Sankoh, S., Wang, Y., Paolino, J., Pasetti, M. F., Feagan, B. G., Parikh, A. Tags: Inflammatory bowel disease Source Type: research